fbpx
The Max Foundation welcomes John Menapace as CFO/VP of Administration

The Max Foundation welcomes John Menapace as CFO/VP of Administration

We are delighted to announce that John Menapace has joined the Max Foundation as CFO/VP of Administration.

John brings demonstrated business leadership to his new role with a background comprising more than 20 years of experience in driving growth and profitability, across Fortune 50, Big 5, non-profit, and start-up companies.  His prior roles include positions of increasing responsibility within such leading organizations as the  American Red Cross, Clinton Health Access Initiative, and Kedrion Biopharma.  Most recently, he was CFO of The Floating Hospital in New York, one of New York City’s oldest healthcare charities with over 150 years of service to the neediest New Yorkers.

“I feel privileged to be joining The Max Foundation team,” says John. “Having worked in several charitable organizations, I am familiar with the Max Foundation’s lifesaving mission of acting as a bridge between patients and treatment while focusing on those no one else is helping. I am honored to be a part of this deeply humanitarian effort and look forward to actively supporting and working towards fulfilling our near- and long-term goals.”

 “We are at a pivotal period of growth and expansion at the Max Foundation, adds Pat Garcia-Gonzales, CEO of the Max Foundation.  “With John’s richly diverse experience including enterprise transformation and creating value across international markets, he is well suited to lead us into this next phase of growth and evolution as we strategically expand our external partnerships and internal talent”.

We’re excited about the depth and caliber of John’s background and look forward to his contributions as we further extend the Max Foundation’s mission of ensuring safe, high-impact medicine for all patients around the globe.

Please join us in welcoming John Menapace to the Max Foundation and wishing him much success.

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 27 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • The Max Foundation (Max) and the International PNH Interest Group (IPIG) Announce Collaboration to Improve Care and Management for People Living with Paroxysmal Nocturnal Hemoglobinuria (PNH) in Low-Resource Countries

    The Max Foundation (Max) and the International PNH Interest Group (IPIG) Announce Collaboration to Improve Care and Management for People Living with Paroxysmal Nocturnal Hemoglobinuria (PNH) in Low-Resource Countries

    IPIG joins Max’s Humanitarian Partnership for Access to Critical Treatments (Humanitarian PACT) and will provide medical education and training on PNH care and management Max will provide access to innovative treatment as part of the multi-stakeholder collaboration focused on eradicating survival disparities in 53 low-resource countries People living with this rare blood disease require frequent….

  • Welcoming Two New Board Members: Dr. Mika Matsuzaki and Dr. Susan M. Jerian

    Please join us in welcoming Mika Matsuzaki, PhD, and Susan M. Jerian, MD to The Max Foundation Board of Directors.

  • The Max Foundation expands collaboration with Pfizer

    The Max Foundation expands collaboration with Pfizer

    The Max Foundation is pleased to announce a significant expansion of its collaboration with Pfizer to provide access to some of Pfizer’s innovative oncology portfolio to patients in low- and middle-income countries, which otherwise would have limited local access. The latest agreement increases the total number of patients benefitting from the program from 270 to 500 patients and adds Inlyta® (axitinib) an oral medicine used to treat advanced kidney cancer.